HYDRALYTE_1170x120

type 2 diabetes

Medicare rolls out diabetes prevention program

Medicare rolls out diabetes prevention program

WASHINGTON — Millions of U.S. seniors can now take part in a Medicare program designed to prevent prediabetes from progressing to type 2 diabetes. Almost half of Americans 65 and older have prediabetes, and many don’t know it. In addition to an increased risk of type 2 diabetes, prediabetes puts people at risk of heart

AstraZeneca releases Bydureon BCise to U.S. pharmacies

AstraZeneca releases Bydureon BCise to U.S. pharmacies

WILMINGTON, Del. — AstraZeneca announced that Bydureon BCise (exenatide extended-release injectable suspension 2 mg) is now available in pharmacies across the United States. Bydureon BCise was recently approved by the U.S. Food and Drug Administration for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral antidiabetic medicines in addition to

Walmart Wellness Day to get more days

Walmart Wellness Day to get more days

BENTONVILLE, Ark. — This year, Walmart is extending the reach of Walmart Wellness Day, billed as the “largest health fair in America.” On June 17, Walmart plans to offer free health screenings — including blood pressure, blood glucose, body mass index (BMI) — at its more than 4,600 stores nationwide from 10 a.m. to 2

Novo Nordisk releases Xultophy 100/3.6 insulin pen

Novo Nordisk releases Xultophy 100/3.6 insulin pen

PLAINSBORO, N.J. — Novo Nordisk has launched Xultophy 100/3.6, a combination therapy insulin pen, at pharmacies nationwide. Xultophy 100/3.6 combines the long-acting basal insulin Tresiba (insulin degludec U-100) with the No. 1-prescribed glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy Victoza (liraglutide 3.6 mg/ml) in a once-daily injection, Novo Nordisk said. The prefilled pen is indicated as

Sanofi launches Soliqua 100/33 insulin pen

Sanofi launches Soliqua 100/33 insulin pen

PARIS — Sanofi has released Soliqua 100/33, an insulin injection for type 2 diabetes, to U.S. pharmacies. The company said Wednesday that Soliqua 100/33 (insulin glargine 100 units/ml and lixisenatide 33 mcg/ml) comes in a single, prefilled SoloStar pen with a dosage range of 15 to 60 units and two starting doses to support patients’

WellDoc, LifeScan team on type 2 diabetes digital solution

WellDoc, LifeScan team on type 2 diabetes digital solution

COLUMBIA, Md. — Health technology provider WellDoc has entered a commercial partnership with LifeScan Inc., a unit of Johnson & Johnson Diabetes Care Cos., to deliver a digital health solution for type 2 diabetes nationwide. Plans call for the companies to integrate WellDoc’s clinically validated BlueStar diabetes management platform and mobile application with LifeScan’s OneTouch

Sanofi cleared by FDA to market Adlyxin

Sanofi cleared by FDA to market Adlyxin

PARIS — Sanofi has gained Food and Drug Administration approval for Adlyxin (lixisenatide), a medication for type 2 diabetes. A once-daily mealtime GLP-1 receptor agonist injection, Adlyxin is indicated as an adjunct to diet and exercise for improving blood glucose control in the treatment of adults with type 2 diabetes.Sanofi said this week that Adlyxin

FDA approves Boehringer Ingelheim, Eli Lilly’s Synjardy

FDA approves Boehringer Ingelheim, Eli Lilly’s Synjardy

RIDGEFIELD, Conn., and INDIANAPOLIS — Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Co. have received approval from the Food and Drug Administration for Synjardy tablets, a medication for type 2 diabetes. The companies said Thursday that Synjardy (empagliflozin and metformin hydrochloride) marks their third product containing empagliflozin to be approved by the FDA, following